


PHARMACEUTICAL 2023



Tyra Biosciences Inc. Rank 16 of 446







PHARMACEUTICAL 2023



Tyra Biosciences Inc. Rank 16 of 446



The relative strengths and weaknesses of Tyra Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Tyra Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 69% points. The greatest weakness of Tyra Biosciences Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 283%, being 240% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	257,288
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,701
Liabilities, Non-Current	2,651
Other Assets	7,816
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	3,602
Other Revenues	0
Property and Equipment	1,077
Research and Development	43,008
Selling, General and Administrative Expense	15,919

Output Variable	Value in 1000 USD
Assets	266,181
Liabilities	8,352
Expenses	58,927
Revenues	0
Stockholders Equity	257,829
Net Income	-55,325
Comprehensive Net Income	-55,325
Economic Capital Ratio	283%

